Indications
Kygevvi is indicated for the treatment of paediatric and adult patients with genetically confirmed thymidine kinase 2 deficiency (TK2d) with an age of symptom onset on or before 12 years.
Composition
- Active substance
- doxecitine, Doxribtimine
- International name (INN)
- doxecitine;doxribtimine
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Kygevvi
- Active substance
- doxecitine, Doxribtimine
- ATC code
- A16AX29
- Therapeutic area
- Mitochondrial Diseases
- Marketing authorisation holder
- UCB Pharma